NRG1 and neoplasm: Further, Zenocutuzumab (MCLA-128), a bispecific monoclonal antibody against ErbB2 and ErbB3, in the eNRGy study (NCT02912949) demonstrated durable efficacy and a well-tolerated safety profile in patients with advanced solid tumors harboring NRG1 fusion, regardless of tumor histology [76].